Mesocel has been developed by LifeCell. It is derived from Mesenchymal Stem Cells obtained from donated umbilical cord tissue. The clinical trial will be conducted in two phases that will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe infection, according to the researchers.
It is a stem cell-based therapy that involves more than 100 million expanded Mesenchymal Stem Cells (MSCs) obtained from donated umbilical cord tissues and are intravenously infused into patients in two doses. The therapy can be undertaken without immune matching between donor and patient.
MSCs isolated from the umbilical cord have a superior expansion capability compared to their adult-sourced counterparts.
“This new cell therapy utilising the potent anti-inflammatory, immune-modulating and tissue regenerative properties of MSCs will further strengthen the fight against COVID and help save lives. Interestingly, similar therapies have already progressed to phase III of clinical trials in other countries—not just for COVID treatment but other associated complications—thus offering great hope for Indian patients,” said Mayur Abhaya, managing director, LifeCell.
LifeCell has set up a manufacturing facility on its Chennai campus that is equipped with multiple bioreactors of different sizes. The facility ensures uninterrupted supply of MSCs for timely and affordable treatment by using the bio-reactors to expand the cells in a sterile environment, thereby providing significant advantages from a cost and quality-control perspective.